Switzerland-based diagnostics firm Biocartis has raised raised €30 million ($41.3 million) in a series B financing round. New investors Debiopharm and Johnson & Johnson Development Corporation joined existing investors in the round.
The personalized medicine company has developed and licensed technologies to build a broadly applicable new diagnostics platform for low to highly multiplexed detection, quantification, and amplification of molecular-based biomarkers, including nucleic acids, proteins, and small molecules. The funding will help Biocartis finalize the development and validation of the first version of its proprietary new platform. "This successful financing, within weeks after closing the acquisition of the Philips technology, is yet another important step in our plans to bring a novel and cost-effective diagnostic solution to the healthcare community," says CEO and founder Rudi Pauwels.
- here's Biocartis' release